Trading Report: The ContraVir Pharmaceuticals Inc (CTRV) Stock Rating Reaffirmed by Maxim Group

The ContraVir Pharmaceuticals Inc (CTRV) Stock Rating Reaffirmed by Maxim Group

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)‘s stock had its “buy” rating reaffirmed by equities researchers at Maxim Group in a research note issued on Thursday. They currently have a $4.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 194.12% from the stock’s current price.

Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up 21.43% during midday trading on Thursday, reaching $1.36. 6,983,513 shares of the company traded hands. The firm’s market capitalization is $72.97 million. ContraVir Pharmaceuticals has a 12-month low of $0.76 and a 12-month high of $2.47. The company has a 50-day moving average of $1.12 and a 200 day moving average of $1.06.

A number of institutional investors have recently added to or reduced their stakes in CTRV. Prospera Financial Services Inc raised its position in ContraVir Pharmaceuticals by 0.6% in the second quarter. Prospera Financial Services Inc now owns 178,550 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 1,000 shares during the last quarter. Vanguard Group Inc. raised its position in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 73,135 shares during the last quarter. Finally, Teachers Advisors Inc. raised its position in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock valued at $1,102,000 after buying an additional 141,368 shares during the last quarter.

About ContraVir Pharmaceuticals

Related posts

Leave a Comment